Cargando…

Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis

BACKGROUND: The subclinical pathophysiology of proliferative lupus nephritis (PLN) has not been fully elucidated. Myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA) is associated with PLN, but prediagnostic levels have not been reported. METHODS: We performed a retrospective case-contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Olson, S. W., Lee, J. J., Poirier, M., Little, D. J., Prince, L. K., Baker, T. P., Edison, J. D., Abbott, K. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757094/
https://www.ncbi.nlm.nih.gov/pubmed/29435367
http://dx.doi.org/10.1155/2017/1872846
_version_ 1783290801421287424
author Olson, S. W.
Lee, J. J.
Poirier, M.
Little, D. J.
Prince, L. K.
Baker, T. P.
Edison, J. D.
Abbott, K. C.
author_facet Olson, S. W.
Lee, J. J.
Poirier, M.
Little, D. J.
Prince, L. K.
Baker, T. P.
Edison, J. D.
Abbott, K. C.
author_sort Olson, S. W.
collection PubMed
description BACKGROUND: The subclinical pathophysiology of proliferative lupus nephritis (PLN) has not been fully elucidated. Myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA) is associated with PLN, but prediagnostic levels have not been reported. METHODS: We performed a retrospective case-control Department of Defense Serum Repository (DoDSR) study comparing MPO-ANCA levels in longitudinal prediagnostic serum samples for 23 biopsy confirmed proliferative lupus nephritis (PLN) patients to DoDSR identified age, sex, race, and age of serum matched healthy and SLE without LN disease controls. We also compared the temporal relationship of MPO-ANCA to anti-double stranded DNA antibodies (dsDNAab). RESULTS: A greater proportion of PLN patients had prediagnostic MPO-ANCA levels above ≥3 U/mL and ≥6 U/mL compared to SLE without LN (91% versus 43%, p < 0.001; 57% versus 5%, p < 0.001, resp.). In subgroup analysis, the MPO-ANCA threshold of ≥3 U/mL was significant at <1 year (88% versus 39%, p = 0.007) and 1–4 years (87% versus 38%, p = 0.009) prior to diagnosis. Statistically significant subclinical MPO-ANCA levels (≥3 U/mL) occurred prior to statistically significant dsDNAab ≥ 3 IU/ml (89% versus 11%, p = 0.003). CONCLUSIONS: Subclinical MPO-ANCA levels could distinguish future PLN from SLE without LN. MPO-ANCA manifests prior to clinical disease and subclinical dsDNAab to suggest that it may contribute directly to PLN pathogenicity.
format Online
Article
Text
id pubmed-5757094
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-57570942018-02-12 Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis Olson, S. W. Lee, J. J. Poirier, M. Little, D. J. Prince, L. K. Baker, T. P. Edison, J. D. Abbott, K. C. Autoimmune Dis Research Article BACKGROUND: The subclinical pathophysiology of proliferative lupus nephritis (PLN) has not been fully elucidated. Myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA) is associated with PLN, but prediagnostic levels have not been reported. METHODS: We performed a retrospective case-control Department of Defense Serum Repository (DoDSR) study comparing MPO-ANCA levels in longitudinal prediagnostic serum samples for 23 biopsy confirmed proliferative lupus nephritis (PLN) patients to DoDSR identified age, sex, race, and age of serum matched healthy and SLE without LN disease controls. We also compared the temporal relationship of MPO-ANCA to anti-double stranded DNA antibodies (dsDNAab). RESULTS: A greater proportion of PLN patients had prediagnostic MPO-ANCA levels above ≥3 U/mL and ≥6 U/mL compared to SLE without LN (91% versus 43%, p < 0.001; 57% versus 5%, p < 0.001, resp.). In subgroup analysis, the MPO-ANCA threshold of ≥3 U/mL was significant at <1 year (88% versus 39%, p = 0.007) and 1–4 years (87% versus 38%, p = 0.009) prior to diagnosis. Statistically significant subclinical MPO-ANCA levels (≥3 U/mL) occurred prior to statistically significant dsDNAab ≥ 3 IU/ml (89% versus 11%, p = 0.003). CONCLUSIONS: Subclinical MPO-ANCA levels could distinguish future PLN from SLE without LN. MPO-ANCA manifests prior to clinical disease and subclinical dsDNAab to suggest that it may contribute directly to PLN pathogenicity. Hindawi 2017 2017-12-24 /pmc/articles/PMC5757094/ /pubmed/29435367 http://dx.doi.org/10.1155/2017/1872846 Text en Copyright © 2017 S. W. Olson et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Olson, S. W.
Lee, J. J.
Poirier, M.
Little, D. J.
Prince, L. K.
Baker, T. P.
Edison, J. D.
Abbott, K. C.
Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis
title Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis
title_full Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis
title_fullStr Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis
title_full_unstemmed Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis
title_short Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis
title_sort anti-myeloperoxidase antibodies associate with future proliferative lupus nephritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757094/
https://www.ncbi.nlm.nih.gov/pubmed/29435367
http://dx.doi.org/10.1155/2017/1872846
work_keys_str_mv AT olsonsw antimyeloperoxidaseantibodiesassociatewithfutureproliferativelupusnephritis
AT leejj antimyeloperoxidaseantibodiesassociatewithfutureproliferativelupusnephritis
AT poirierm antimyeloperoxidaseantibodiesassociatewithfutureproliferativelupusnephritis
AT littledj antimyeloperoxidaseantibodiesassociatewithfutureproliferativelupusnephritis
AT princelk antimyeloperoxidaseantibodiesassociatewithfutureproliferativelupusnephritis
AT bakertp antimyeloperoxidaseantibodiesassociatewithfutureproliferativelupusnephritis
AT edisonjd antimyeloperoxidaseantibodiesassociatewithfutureproliferativelupusnephritis
AT abbottkc antimyeloperoxidaseantibodiesassociatewithfutureproliferativelupusnephritis